R&D channel feed

New study shows small­er bio­phar­ma com­pa­nies strug­gle more than larg­er ones with clin­i­cal tri­al trans­paren­cy

4 years ago
FDA+

Cy­to­ki­net­ics is get­ting its shot at a ma­jor PhI­II show­down with Bris­tol My­ers af­ter post­ing pos­i­tive da­ta for a rare car­dio dis­ease. Shares rock­et up

4 years ago

Glax­o­SmithK­line trum­pets a PhI­II win in one of Hal Bar­ron's hand­picked drugs, a day af­ter Fi­bro­Gen's face­plant. Will it mat­ter enough to crit­ics?

4 years ago

Bris­tol My­ers Squibb takes an­oth­er late-stage loss for Op­di­vo-Yer­voy com­bo in head and neck can­cer

4 years ago
Pharma

A cou­ple weeks af­ter ac­tivist at­tack, Glax­o­SmithK­line un­veils big plans to cre­ate a UK biotech hub

4 years ago

Alex­ion touts new PhI­II da­ta of Soliris suc­ces­sor as planned As­traZeneca takeover looms

4 years ago

CD­MO AM­RI re­brands and snags a pair of small­er com­pa­nies to aid its shift to be­come a glob­al brand name

4 years ago
Manufacturing

Gen­er­a­tion Bio snaps up Boston area plant as it rolls out a man­u­fac­tur­ing process it thinks will be a game chang­er

4 years ago
Manufacturing

Gala­pa­gos dis­ap­points again as 2 key read­outs fail to gen­er­ate much en­thu­si­asm for Gilead­'s fad­ing part­ner

4 years ago

Tom Lynch moves to re­struc­ture Fred Hutch as acad­e­mia, in­dus­try con­tin­ue to push cell ther­a­py in­to sol­id tu­mors

4 years ago

Bank­ing on shared ex­pe­ri­ences — and now a big in­vestor — with broth­er Vivek, Shankar Ra­maswamy stacks up a $100M mega-round

4 years ago

In mul­ti­ple myelo­ma show­down, J&J adds an­oth­er feath­er to Darza­lex's cap

4 years ago
FDA+

Switch­ing fo­cus in the brain, re­searchers her­ald a pos­si­ble gene ther­a­py break­through in treat­ing an ul­tra-rare dis­ease

4 years ago
Cell/Gene Tx

Aim­ing to re­bound from blun­ders years ago, Celldex touts a Phase Ib win with sights set on Xo­lair

4 years ago

Ovid shuf­fles C-suite, lays off staff in wake of PhI­II An­gel­man syn­drome fail

4 years ago
People
Pharma

Of­ten-passed plant in Col­orado has a new own­er, who's al­ready op­er­at­ing near­by

4 years ago
Manufacturing

J&J, Sid Mukher­jee's Vor team up to pair bis­pecifics with en­gi­neered stem cells for blood can­cer

4 years ago
Deals

A bright fu­ture for LAG-3? Top an­a­lysts see an arms race in the mak­ing, but drug­mak­ers need a bi­ol­o­gy break­through

4 years ago

On­copep­tides says a sec­ond look at its da­ta of­fers a win in head-to-head can­cer tri­al — but key OS flop trig­gers a hold

4 years ago
FDA+

Mod­er­na puts a sea­son­al flu vac­cine in the clin­ic as ex­ecs hope to open chap­ter 2 of their block­buster vac­cine sto­ry

4 years ago

The top 10 pipeline blowups, set­backs and sna­fus for H1 2021

4 years ago
Special

Guid­ance bo­nan­za: FDA, EMA, MHRA, Health Cana­da and PIC/S of­fer new ad­vice on a range of phar­ma is­sues

4 years ago
FDA+

Af­ter de­lay caused by Ital­ian CD­MO, No­var­tis moves man­u­fac­tur­ing to Aus­tri­an site

4 years ago
Manufacturing

Eli Lil­ly, Boehringer In­gel­heim tout piv­otal heart fail­ure win for Jar­diance, po­ten­tial­ly set­ting up a No­var­tis show­down

4 years ago
Pharma
First page Previous page 164165166167168169170 Next page Last page
A service from the Financial Times